Discover 775 paid clinical trials in Washington, D.C.. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 775
Active & Responsive
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
for
Chondral Defect, Articular Cartilage Defect
Location: Washington D.C. DC, Charlottesville VA, Pittsburgh PA,
Sponsor: Vericel Corporation
Sex: All
Age: 17 - 65
Code: NCT06915233
Phase 3, Recruiting
Active & Responsive
Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer
for
Metastatic Colorectal Adenocarcinoma,
Location: Washington D.C. DC, Baltimore MD, Atlanta GA, Aurora CO
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07147231
Phase 1, Phase 2, Recruiting
Active & Responsive
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
for
Extensive Stage Lung Small Cell Carcinoma,
Location: Washington D.C. DC, Baltimore MD, Richmond VA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06287775
Phase 1, Phase 2, Recruiting
Active & Responsive
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
for
Sickle Cell Disease
Location: Washington D.C. DC, Baltimore MD, Philadelphia PA,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 12 - 70+
Code: NCT06439082
Phase 3, Recruiting
Active & Responsive
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
for
Neuroblastoma, Sarcoma
Location: Washington D.C. DC, The Bronx NY, Columbus OH,
Sponsor: Nationwide Children's Hospital
Sex: All
Age: 1 - 40
Code: NCT05135975
Phase 2, Recruiting
Active & Responsive
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Location: Washington D.C. DC, Baltimore MD, New York NY,
Sponsor: Carl Allen
Sex: All
Age: 0+
Code: NCT04079179
Phase 2, Recruiting
Active & Responsive
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
for
Familial Hypercholesterolemia - Homozygous
Location: Washington D.C. DC, St Louis MO, Salt Lake City UT,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 2 - 11
Code: NCT06597006
Phase 3, Recruiting
Active & Responsive
Advancing Transplantation Outcomes in Children
for
Kidney Transplant
Location: Washington D.C. DC, Baltimore MD, Wilmington DE,
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All
Age: 13 - 20
Code: NCT06055608
Phase 2, Recruiting
Active & Responsive
Family Intervention for Black Teens With Type 1 Diabetes
for
Type 1 Diabetes, Family Relations
Location: Washington D.C. DC, Detroit MI, Memphis TN
Sponsor: Wayne State University
Sex: All
Age: 10 - 14
Code: NCT06275412
Recruiting
Active & Responsive
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
for
Diffuse Midline Glioma (DMG), Glioblastoma,
Location: Washington D.C. DC, Philadelphia PA, Ann Arbor MI,
Sponsor: Sabine Mueller, MD, PhD
Sex: All
Age: 2 - 21
Code: NCT04732065
Phase 1, Recruiting
Active & Responsive
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
for
Juvenile Psoriatic Arthritis
Location: Washington D.C. DC, New York NY, Valhalla NY,
Sponsor: AbbVie
Sex: All
Age: 5 - 17
Code: NCT06100744
Phase 3, Recruiting
Active & Responsive
BBD Longitudinal Study of Osteogenesis Imperfecta
for
Osteogenesis Imperfecta
Location: Washington D.C. DC, Baltimore MD, Wilmington DE,
Sponsor: Baylor College of Medicine
Sex: All
Age: 0+
Code: NCT02432625
Recruiting
Active & Responsive
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
for
Heart Block Complete, Heart Block Second Degree
Location: Washington DC, New York NY, Toronto, Boston MA,
Sponsor: The Hospital for Sick Children
Sex: Female
Age: 16 - 50
Code: NCT04559425
Recruiting
Active & Responsive
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
for
End Stage Renal Disease
Location: Washington DC, Charlotte NC, Cincinnati OH,
Sponsor: Rockwell Medical Technologies, Inc.
Sex: All
Age: 0 - 17
Code: NCT04239391
Phase 3, Recruiting
Active & Responsive
Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)
for
DMG, DIPG
Location: Washington D.C. DC
Sponsor: Children's National Research Institute
Sex: All
Age: 3 - 25
Code: NCT07796061
Phase 1, Recruiting
Active & Responsive
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
for
Malignant Peripheral Nerve Sheath Tumor (MPNST),
Location: Washington D.C. DC, Dallas TX
Sponsor: AeRang Kim
Sex: All
Age: 18+
Code: NCT06735820
Phase 1, Phase 2, Recruiting
Active & Responsive
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
for
PIK3CA-related Overgrowth Spectrum (PROS)
Location: Washington D.C. DC, Pittsburgh PA, Chapel Hill NC,